Cargando…

Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice

For proper cholesterol metabolism, normal expression and function of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor, is required. Among the factors that regulate overall cholesterol homeostasis and HDL metabolism, the nuclear farnesoid X receptor plays an import...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiva, Andrea, Contreras-Duarte, Susana, Amigo, Ludwig, Sepúlveda, Esteban, Boric, Mauricio, Quiñones, Verónica, Busso, Dolores, Rigotti, Attilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598962/
https://www.ncbi.nlm.nih.gov/pubmed/28910310
http://dx.doi.org/10.1371/journal.pone.0184280
_version_ 1783264008844869632
author Leiva, Andrea
Contreras-Duarte, Susana
Amigo, Ludwig
Sepúlveda, Esteban
Boric, Mauricio
Quiñones, Verónica
Busso, Dolores
Rigotti, Attilio
author_facet Leiva, Andrea
Contreras-Duarte, Susana
Amigo, Ludwig
Sepúlveda, Esteban
Boric, Mauricio
Quiñones, Verónica
Busso, Dolores
Rigotti, Attilio
author_sort Leiva, Andrea
collection PubMed
description For proper cholesterol metabolism, normal expression and function of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor, is required. Among the factors that regulate overall cholesterol homeostasis and HDL metabolism, the nuclear farnesoid X receptor plays an important role. Guggulsterone, a bioactive compound present in the natural product gugulipid, is an antagonist of this receptor. This natural product is widely used globally as a natural lipid-lowering agent, although its anti-atherogenic cardiovascular benefit in animal models or humans is unknown. The aim of this study was to determine the effects of gugulipid on cholesterol homeostasis and development of mild and severe atherosclerosis in male mice. For this purpose, we evaluated the impact of gugulipid treatment on liver histology, plasma lipoprotein cholesterol, endothelial function, and development of atherosclerosis and/or ischemic heart disease in wild-type mice; apolipoprotein E knockout mice, a model of atherosclerosis without ischemic complications; and SR-B1 knockout and atherogenic–diet-fed apolipoprotein E hypomorphic (SR-BI KO/ApoER61(h/h)) mice, a model of lethal ischemic heart disease due to severe atherosclerosis. Gugulipid administration was associated with histological abnormalities in liver, increased alanine aminotransferase levels, lower hepatic SR-BI content, hypercholesterolemia due to increased HDL cholesterol levels, endothelial dysfunction, enhanced atherosclerosis, and accelerated death in animals with severe ischemic heart disease. In conclusion, our data show important adverse effects of gugulipid intake on HDL metabolism and atherosclerosis in male mice, suggesting potential and unknown deleterious effects on cardiovascular health in humans. In addition, these findings reemphasize the need for rigorous preclinical and clinical studies to provide guidance on the consumption of natural products and regulation of their use in the general population.
format Online
Article
Text
id pubmed-5598962
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55989622017-09-22 Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice Leiva, Andrea Contreras-Duarte, Susana Amigo, Ludwig Sepúlveda, Esteban Boric, Mauricio Quiñones, Verónica Busso, Dolores Rigotti, Attilio PLoS One Research Article For proper cholesterol metabolism, normal expression and function of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor, is required. Among the factors that regulate overall cholesterol homeostasis and HDL metabolism, the nuclear farnesoid X receptor plays an important role. Guggulsterone, a bioactive compound present in the natural product gugulipid, is an antagonist of this receptor. This natural product is widely used globally as a natural lipid-lowering agent, although its anti-atherogenic cardiovascular benefit in animal models or humans is unknown. The aim of this study was to determine the effects of gugulipid on cholesterol homeostasis and development of mild and severe atherosclerosis in male mice. For this purpose, we evaluated the impact of gugulipid treatment on liver histology, plasma lipoprotein cholesterol, endothelial function, and development of atherosclerosis and/or ischemic heart disease in wild-type mice; apolipoprotein E knockout mice, a model of atherosclerosis without ischemic complications; and SR-B1 knockout and atherogenic–diet-fed apolipoprotein E hypomorphic (SR-BI KO/ApoER61(h/h)) mice, a model of lethal ischemic heart disease due to severe atherosclerosis. Gugulipid administration was associated with histological abnormalities in liver, increased alanine aminotransferase levels, lower hepatic SR-BI content, hypercholesterolemia due to increased HDL cholesterol levels, endothelial dysfunction, enhanced atherosclerosis, and accelerated death in animals with severe ischemic heart disease. In conclusion, our data show important adverse effects of gugulipid intake on HDL metabolism and atherosclerosis in male mice, suggesting potential and unknown deleterious effects on cardiovascular health in humans. In addition, these findings reemphasize the need for rigorous preclinical and clinical studies to provide guidance on the consumption of natural products and regulation of their use in the general population. Public Library of Science 2017-09-14 /pmc/articles/PMC5598962/ /pubmed/28910310 http://dx.doi.org/10.1371/journal.pone.0184280 Text en © 2017 Leiva et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Leiva, Andrea
Contreras-Duarte, Susana
Amigo, Ludwig
Sepúlveda, Esteban
Boric, Mauricio
Quiñones, Verónica
Busso, Dolores
Rigotti, Attilio
Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice
title Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice
title_full Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice
title_fullStr Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice
title_full_unstemmed Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice
title_short Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice
title_sort gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598962/
https://www.ncbi.nlm.nih.gov/pubmed/28910310
http://dx.doi.org/10.1371/journal.pone.0184280
work_keys_str_mv AT leivaandrea gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT contrerasduartesusana gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT amigoludwig gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT sepulvedaesteban gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT boricmauricio gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT quinonesveronica gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT bussodolores gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice
AT rigottiattilio gugulipidcauseshypercholesterolemialeadingtoendothelialdysfunctionincreasedatherosclerosisandprematuredeathbyischemicheartdiseaseinmalemice